Nebivolol information

Nebivolol
Clinical data
Trade names	Nebilet, Bystolic, others
Other names	Narbivolol, Nebivolol, Nebivololum
AHFS/Drugs.com	Monograph
MedlinePlus	a608029
License data	US DailyMed: Nebivolol;
Pregnancy; category	AU: C; ;
Routes of; administration	By mouth
ATC code	C07AB12 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Protein binding	98%
Metabolism	Liver (CYP2D6-mediated)
Elimination half-life	12-19 hours
Excretion	Kidney and fecal
Identifiers
CAS Number	118457-14-0 ;
PubChem CID	71301;
IUPHAR/BPS	7246;
DrugBank	DB04861 ;
ChemSpider	64421 ;
UNII	030Y90569U;
KEGG	D05127 ; as HCl: D06622 ;
ChEMBL	ChEMBL434394 ;
CompTox Dashboard (EPA)	DTXSID9040556 ;
Chemical and physical data
Formula	C22H25F2NO4
Molar mass	405.442 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc4cc1c(OC(CC1)C(O)CNCC(O)C3Oc2ccc(F)cc2CC3)cc4;
	InChI InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2 ; Key:KOHIRBRYDXPAMZ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Nebivolol is a beta blocker used to treat high blood pressure and heart failure.^[5] As with other β-blockers, it is generally a less preferred treatment for high blood pressure.^[6] It may be used by itself or with other blood pressure medication.^[6] It is taken by mouth.^[6]

Common side effects include dizziness, feeling tired, nausea, and headaches.^[6] Serious side effects may include heart failure and bronchospasm.^[6] Its use in pregnancy and breastfeeding is not recommended.^[5]^[7] It works by blocking β1-adrenergic receptors in the heart and dilating blood vessels.^[6]^[8]

Nebivolol was patented in 1983 and came into medical use in 1997.^[9] It is available as a generic medication in the United Kingdom.^[5] In 2021, it was the 244th most commonly prescribed medication in the United States, with more than 1 million prescriptions.^[10]^[11]

^ "Nebivolol". go.drugbank.com. Retrieved 17 August 2022.
^ "Drugs@FDA: FDA-Approved Drugs Nebivolol - ALLERGAN" (PDF). accessdata.fda.gov. Retrieved 17 August 2022.
^ Giles TD, Cockcroft JR, Pitt B, Jakate A, Wright HM (September 2017). "Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data". Journal of Hypertension. 35 (9): 1758–1767. doi:10.1097/HJH.0000000000001412. PMC 5548499. PMID 28509722.
^ "DrugBank Nebivolol". go.drugbank.com. Retrieved 17 August 2022.
^ ^a ^b ^c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 154. ISBN 9780857113382.
^ ^a ^b ^c ^d ^e ^f "Nebivolol Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
^ "Nebivolol Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
^ de Boer RA, Voors AA, van Veldhuisen DJ (July 2007). "Nebivolol: third-generation beta-blockade". Expert Opinion on Pharmacotherapy. 8 (10): 1539–1550. doi:10.1517/14656566.8.10.1539. PMID 17661735. S2CID 24186687.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 462. ISBN 9783527607495.
^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
^ "Nebivolol - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

[1] "Nebivolol". go.drugbank.com. Retrieved 17 August 2022.

[2] "Drugs@FDA: FDA-Approved Drugs Nebivolol - ALLERGAN" (PDF). accessdata.fda.gov. Retrieved 17 August 2022.

[3] Giles TD, Cockcroft JR, Pitt B, Jakate A, Wright HM (September 2017). "Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data". Journal of Hypertension. 35 (9): 1758–1767. doi:10.1097/HJH.0000000000001412. PMC 5548499. PMID 28509722.

[4] "DrugBank Nebivolol". go.drugbank.com. Retrieved 17 August 2022.

[BNF76-5] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 154. ISBN 9780857113382.

[AHFS2019-6] ^ ^a ^b ^c ^d ^e ^f "Nebivolol Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.

[Preg2019-7] "Nebivolol Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.

[De2007-8] Boer RA, Voors AA, van Veldhuisen DJ (July 2007). "Nebivolol: third-generation beta-blockade". Expert Opinion on Pharmacotherapy. 8 (10): 1539–1550. doi:10.1517/14656566.8.10.1539. PMID 17661735. S2CID 24186687.

[9] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 462. ISBN 9783527607495.

[10] "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.

[11] "Nebivolol - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

Nebivolol information

and 28 Related for: Nebivolol information

Nebivolol

Hydralazine

ATC code C07

Chromane

Beta blocker

Valsartan

Rilmenidine

Hydrochlorothiazide

Bisoprolol

ATC code C09

Promethazine

LSD

Hydroxyzine

Propranolol

Tizanidine

Norepinephrine

Sildenafil

Chlorpromazine

Olanzapine

Mirabegron

Clozapine

List of cardiac pharmaceutical agents

Benzylamine

Bupropion

Carvedilol

Nitrate

Salbutamol

Nitroglycerin